Recent Updates
Recently added Catalysts

DTwP-HepB-Hib Vaccine

Phase 3

Diphtheria | Monoclonal antibody | Infectious Disease |Novartis AG|Last Updated: May 19, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment175
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01470287Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of AgePHASE3 COMPLETED 175Dec 1, 2011Apr 1, 2012May 19, 20173 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Seroprotection rate one month after the last dose of vaccine administration
One month after last vaccination
Secondary Endpoints
Seroprotection rate and GMCs one month after the last vaccine administration
One month after last vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Arm 1EXPERIMENTAL -
Interventions
NameTypeDescription
DTwP-HepB-Hib VaccineBIOLOGICALOpen label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
Unlock Study Design Details
Eligibility Criteria
Age Range42 Days — 64 Days
SexALL
Healthy VolunteersYes
Study Sites3

Inclusion Criteria: 1. Male and female subjects ≥ 42 days to ≤ 64 days of age. 2. Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements Exclusion Criteria: 1. Subjects whose parents or lega...

Countries:India
Unlock Eligibility Criteria